To investigate the long-term safety and tolerability of BI 10773 10 and 25 mg once daily
Data and Resources
- A phase III double-blind extension placebo-controlled parallel group safety and efficacy trial of BI 10773 10 and 25mg once daily and sitagliptin 100mg once daily given for minimum 76 weeks incl 24 weeks of preceding trial as monotherapy or with...json
To investigate the long-term safety and tolerability of BI 10773 10 and 25...
|Release Date|| |
|Public Access Level|| |